⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

AUROPHARMA - IntraDay Trade Analysis with Live Signals

← Back to List

⭐ Rating: 4

Last Updated Time : 19 Sept 26, 08:06 am

Key Parameters

⭐ IntraDay Trade Rating: 4.0

RSI63.2
MACD21.2
Volume12,45,440
Avg Vol 1Wk7,49,292
Low price1,066 ₹
High price1,735 ₹
Current Price1,735 ₹
DMA 501,620 ₹
Show all parameters (20 more)
Stock CodeAUROPHARMA
Market Cap1,00,187 Cr.
High / Low1,735 ₹
Stock P/E38.4
Book Value391 ₹
Dividend Yield0.23 %
ROCE13.0 %
ROE11.2 %
Face Value1.00 ₹
DMA 2001,441 ₹
Chg in FII Hold1.14 %
Chg in DII Hold-0.77 %
PAT Qtr737 Cr.
PAT Prev Qtr692 Cr.
PEG Ratio1.49
Debt to equity0.19
52w Index100 %
Qtr Profit Var31.8 %
EPS44.8 ₹
Industry PE34.8

🧾 Trade Setup

Buy at 1730 ₹ with a stop-loss order set at 1715 ₹. Target price 1760 ₹ – utilize the recent momentum for an immediate profit target. If the stock stalls below 1715 ₹, tighten the stop-loss to 1705 ₹ to protect capital. Overall, this is a high-risk, high-reward opportunity given the strong volume and positive catalyst.

✅ Positive

The recent USFDA approval for a new inhalation aerosol product is a strong positive, driving immediate upward momentum. Furthermore, the stock is trading near its 52-week high and experiencing elevated volume – this suggests significant buying interest.

⚠️ Limitation

Despite the positive news and strong volume, the extremely high P/E ratio of 38.4 relative to the industry PE of 34.8 indicates a premium valuation that could present a challenge if momentum stalls. The RSI is also quite high at 63.2, potentially signaling overbought conditions and increasing the risk of a pullback.

📈 Company Positive News

The USFDA approval for the inhalation aerosol product provides an immediate catalyst for price increases, supported by the stock trading near its 52-week high.

🏭 Industry

The pharmaceutical sector, particularly generic drug manufacturers like Aurobindo Pharma, is generally bullish due to increasing demand for affordable medications and ongoing regulatory approvals boosting revenue. However, investor sentiment can be volatile given patent expirations and competition within the industry.

Choose Technical Analysis or Fundamental Analysis above to load it.

How AUROPHARMA Rates Across All Strategies

★ 4.0
Entry Price: 1735 ₹.
Intraday
★ 4.0
You're viewing this analysis below.
★ 3.8
An ideal entry zone would be between 1,600 ₹ and 1,700 ₹, capitalizin…
★ 4.2
Short-term entry zones could be established between 1700 ₹ and 1735 ₹…
★ 4.0
We recommend an entry zone between 1,600 ₹ and 1,650 ₹ based on the c…

NIFTY 50 · Intraday Trading

NEXT 50 · Intraday Trading

MIDCAP · Intraday Trading

SMALLCAP · Intraday Trading